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Identification of proprotein convertase substrates
using genome-wide expression correlation
analysis
Hannu Turpeinen1,2, Sampo Kukkurainen2,3†, Kati Pulkkinen1,2†, Timo Kauppila1,2,3, Kalle Ojala4, Vesa P Hytönen2,3
and Marko Pesu1,2,5*
Abstract
Background: Subtilisin/kexin-like proprotein convertase (PCSK) enzymes have important regulatory function in a
wide variety of biological processes. PCSKs proteolytically process at a target sequence that contains basic amino
acids arginine and lysine, which results in functional maturation of the target protein. In vitro assays have showed
significant biochemical redundancy between the seven family members, but the phenotypes of PCSK deficient
mice and patients carrying an inactive PCSK allele argue for a specific biological function. Modeling the structures
of individual PCSK enzymes has offered little insights into the specificity determinants. However, previous studies
have shown that there can be a coordinated expression between a PCSK and its target molecule. Here, we have
surveyed the putative PCSK target proteins using genome-wide expression correlation analysis and cleavage site
prediction algorithms.
Results: We first performed a gene expression correlation analysis over the whole genome for all PCSK enzymes.
PCSKs were found to cluster differently based on the strength of correlations. The screen for putative PCSK target
proteins showed a significant enrichment (p-values from 1.2e-4 to < 1.0e-10) of putative targets among the most
positively correlating genes for most PCSKs. Interestingly, there was no enrichment in putative targets among the
genes that correlated positively with the biologically redundant PCSK7, whereas PCSK5 showed an inverse
correlation. PCSKs also showed a highly variable degree of shared target genes that were identified by expression
correlation and cleavage site prediction. Multiple alignments were used to evaluate the putative targets to pinpoint
the important residues for the substrate recognition. Finally, we validated our approach and identified
biochemically PAPPA1 and ADAMTS6 as novel targets for FURIN proteolytic activity.
Conclusions: Most PCSK enzymes display strong positive expression correlation with predicted target proteins in
our genome-wide analysis. We also show that expression correlation screen combined with a cleavage site-
prediction analysis can be used to identify novel bona fide target molecules for PCSKs. Exploring the positively
correlating genes can thus offer additional insights into the biology of proprotein convertases.
Background
Many proteins that control biological processes are initi-
ally synthesized as immature proproteins, which need to
be proteolytically converted into functional end pro-
ducts. This proprotein conversion dictates the bioavail-
ability of these dormant molecules. Therefore the
enzymes responsible of this event, proprotein conver-
tases (PCSK), are important regulatory factors. The pri-
marily identified seven PCSKs (PCSK1-2, FURIN,
PCSK4-7) are closely related and evolutionarily con-
served subtilisin/kexin-like serine proteases that process
their targets mainly in the secretory pathway, cell sur-
face and endosomes (reviewed in [1,2]). The general
PCSK target sequence typically encompasses a series of
basic amino acids lysine and/or arginine; (K/R)-(X)n-(K/
R)↓, where n is 0, 2, 4 or 6 and X is any amino acid.
More recently identified and distantly related PCSK
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family members MBTPS1 and PCSK9 do not cleave at
basic amino acids. Instead, MBTPS1 targets the consen-
sus motif (R/K)-X-(hydrophobic)-X↓, and PCSK9 has
only autocatalytic cleavage activity on its prosegment
sequence VFAQ152↓.
Understanding the determinants of PCSK target speci-
ficity is currently incomplete; convertases have shown a
variable degree of redundancy in target selection in in
vitro experiments, especially in over-expression settings
[3,4]. Importantly, however, the phenotypes of PCSK
deficient animals and patients with genetic mutations
that result in abolished or enhanced PCSK activity show
compellingly that most, if not all, family members also
have specific target proteins [5]. One approach to gain
insights into the specificity prerequisites is to model and
compare the structures of the PCSK enzymes. Previous
results suggest that all human PCSKs share a remarkably
similar structure of the substrate binding groove and
there are only subtle differences in the number of
charged residues close to the substrate binding region [6].
Additional clues for identification of physiological
PCSK - substrate pairs come from experiments that
show a positive expression correlation between PCSK
and its substrate in cell. For example, FURIN is co-
expressed with its target molecule VEGF-C in head and
neck cancer [7], and some targets, like TGFb-1, are even
known to create a feed-forward mechanism by enhan-
cing the expression of their converting enzyme (FURIN)
[8]. An explanation for the coordinated expression is
often the common transcription factors that regulate the
expression of both PCSK and a target molecule [9,10].
However, whether this phenomenon is universal for all
PCSKs and indicative of biological substrate specificity is
currently not known.
In order to find new PCSK - target molecule pairs we
have here analyzed the genome-wide expression correla-
tion for all human genes and PCSK enzymes in a very
large number of samples. Our results also show that
with notable exception of PCSK5 and PCSK7 the genes
that are strongly co-regulated with a certain PCSK are
often putative target molecules for these enzymes. We
found also that PCSKs display a highly variable number
of unique and shared target genes, and that they also
cluster differently with regard how many genes show a
strong expression correlation. We finally validate our
approach in biochemical experiments and identify
PAPPA1 and ADAMTS6 as novel FURIN target
molecules.
Results and Discussion
The crystal structures for mouse FURIN, bacterial SUB-
TILISIN and yeast KEXIN have been previously deter-
mined using X-ray crystallography [11-13]. We used the
mouse FURIN structure as a template to survey the con-
servation of enzymatically active cleft/pocket of all the
PCSK homologues in different genomes (152 sequences,
Figure 1, Additional File 1). We found the catalytic cleft,
especially the residues that are in contact with the P1-
P4 sites of the substrate, to be highly conserved in all
PCSKs over different genomes. Our data further corro-
borate the remarkable conservation of the catalytically
active cleft of the PCSK enzymes and suggest that the
PCSK substrate specificity is likely not solely explained
by the structural features of the active site [6].
Figure 1 Conservation of the PCSK catalytic domain. The 3D-structure of mouse FURIN is shown as surface (left) and cartoon (right)
presentation and the bound inhibitor as purple stick model. Amino acids identical in >95% of the 152 related PCSK sequences are marked with
green color, indicating highly conserved active site. Sequences that were used for the analysis are available in the Additional File 1. Some of the
conserved residues are labeled using the FURIN numbering.
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Expression correlation
Meta-analyses of public microarray data sources offer
insights into the genome-wide gene expression in health
and disease [14,15]. GeneSapiens is a comprehensive
reference database of the human transcriptome that
integrates large quantities of human expression data
into a unified format [16]. Using GeneSapiens we first
arranged the whole human transcriptome (17330 genes)
according to expression similarity with PCSK genes in
all healthy tissues (Figure 2, Additional File 2). The
average correlation between PCSKs and all other genes
was close to zero (range -0.02 - 0.04). The 5% (867
genes, 861 for PCSK4) of both most positively (hereafter
“top 5%”) and negatively ("bottom 5%”) correlating
genes were chosen for further analysis.
Marked differences were observed in the magnitude of
correlation amongst the top 5% genes. Average correla-
tions fell into two distinct categories: PCSK1, PCSK2
and PCSK6 cluster together with significantly higher
average correlations (0.57, 0.66 and 0.44, respectively)
than FURIN (0.40), PCSK4 (0.36), PCSK5 (0.30) and
PCSK7 (0.39). PCSK2 stands out from all the other
PCSKs with 66 genes with an extreme high genome-
wide expression correlation value of >0.8 (Additional
File 2, Figure 3). In contrast, no such high correlations
were observed for FURIN, PCSK4, PCSK5 or PCSK7,
whereas PCSK1 and PCSK6 had only a few genes with
equally high correlation (Additional File 2). The genes
that had the strongest negative expression correlation
with PCSKs (bottom 5% genes) showed less variation in
their magnitude of correlation (average correlations in
groups between -0.29 and -0.39, Figure 3).
Finally, we explored the strength of the expression
correlation between the PCSK genes. Our data show
that apart from PCSK1 and PCSK2 enzymes, which are
chiefly present in the neuroendocrine tissues, no other
PCSK-PCSK pair ranks within either top or bottom 5%
in the analyses over the whole spectrum of tissues
(Additional File 3). It is noteworthy, however, that when
PCSK pairs were analyzed in a tissue specific setting
other strong correlations can be observed. For example,
FURIN and PCSK6 show highly significant correlation
in blood myeloid cells (n = 156, r = 0.634, p = 0). Tissue
specific expression correlation data for all PCSK pairs is
shown in Additional File 4.
Identification of putative PCSK targets
The scheme that PCSK enzymes are co-expressed with
their target molecules in vivo is supported by experi-
mental evidence where immature growth factors are
shown to be co-expressed and even induce the expres-
sion of their converting enzyme [7,8]. We wanted to
explore whether putative PCSK target molecules are
generally enriched in the genes that are coordinately
expressed with PCSK enzymes. To this end, we
employed a previously published, artificial neural net-
works based method (ProP 1.0, http://www.cbs.dtu.dk/
services/ProP/, [17]) to survey PCSK target sequences in
the most positively and negatively co-expressed genes.
In addition, since PCSK mostly process their target pro-
teins in the secretory pathway, the presence of signal
peptide sequence predicted using the SignalP algorithm
integrated in ProP 1.0 was used as an additional inclu-
sion criterion for putative targets [18].
Our analysis show that with the exception of PCSK5
and PCSK7 the top 5% of positively correlating gene
pools encompasses a significant enrichment of putative
target genes when compared with the bottom 5% corre-
lates (Table 1, Additional File 2 for identity of putative
target molecules). For FURIN we used both “general
PC” network, which is based on the experimental crystal
structures in Swiss-Prot protein database and experi-
ment-based “FURIN specific” target prediction network;
both analyses showed strong enrichment of putative tar-
gets in highly positively correlating genes. Interestingly,
PCSK7, the only family member with no reported
Figure 2 An example picture of whole genome expression correlation with a PCSK gene. Top 5% and bottom 5% of correlating genes
were selected for further investigations.
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knock-out mouse phenotype or specific target genes
[19,20], showed no significant difference in the number
of putative target genes in top 5% versus bottom 5%
correlates (p = 0.713). This finding may either further
suggest redundancy for PCSK7 function in biology or be
a sign of more limited number of target molecules.
PCSK5 in part showed an outstanding number of puta-
tive target molecules amongst the negatively correlating
genes. This is an intriguing phenomenon and may offer
insights into the biological characteristics of this
enzyme. For example, one could envision that the
PCSK5 target mRNA translation may become repressed
Figure 3 Top 5% and bottom 5% correlating genes with PCSK genes. An average expression correlation is shown for each group as a
horizontal line.
Table 1 Basic information on PCSK genes and whole genome expression correlations
Top 5% (n = 861/867) Bottom 5% (n = 861/867)
gene id # correlating
genes in
GeneSapiens
(5%)
# of common
samples with
other genes
# genes with furin/
general PC cleavage
site and signal peptide
max/min
correlation
# genes with furin/
general PC
cleavage site and
signal peptide
max/min
correlation
p
value*
PCSK1 ensg00000175426 17330 (867) 445-1698 160 0.810/0.450 102 -0.246/-0.479 1.24E-4
PCSK2 ensg00000125851 17330 (867) 445-1698 170 0.871/0.541 96 -0.334/-0.637 5.10E-7
FURIN ensg00000140564 17330 (867) 445-1698 161 0.652/0.332 83 -0.253/-0.512 4.21E-9/
2.10E-7
PCSK4 ensg00000115257 17215 (861) 497-668 104 0.592/0.300 67 -0.236/-0.480 2.25E-4
PCSK5 ensg00000099139 17330 (867) 445-1698 116 0.636/0.232 158 -0.245/-0.493 4.45E-3
PCSK6 ensg00000140479 17330 (867) 445-1698 165 0.833/0.302 60 -0.277/-0.526 < 1E-10
PCSK7 ensg00000160613 17330 (867) 445-1698 111 0.571/0.312 109 -0.236/-0.481 0.71
Genes with PCSK cleavage site and signal peptide accumulate in top 5% correlating genes
* Chi-square test for top 5% vs bottom 5% correlating genes/fraction of genes with PCSK detection site and signal peptide from all 5% genes.
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if mature protein is expressed in abundance. This could
lead to lack of target enrichment in the positively corre-
lating gene pool. We tested this hypothesis by exploring
how an experimentally identified and bottom 5% target
protein BACE1 [21] affects the PCSK5 expression in
293e cells. In these experiments transient overexpression
of BACE1 did not cause any alterations in the PCSK
mRNA expression levels (data not shown). This negative
result could, in theory, imply that the target induced
PCSK5 repression is either tissue or target dependent,
or that PCSK5 downregulation requires a sustained
expression of its target proteins.
PCSK enzymes have displayed a significant level of
redundancy between family members in vitro [4]. How-
ever, the phenotypes of PCSK knockout animals and
patients with either gain or loss-of-function mutations
in PCSK genes argue for target specificity and need for
identification of specific enzyme-substrate pairs [22,23].
To gain insights into the PCSK substrate specificity we
first analyzed the degree of shared putative target pro-
teins identified in expression-correlation analysis. Table
2 lists the fractions of common putative targets for each
PCSK enzyme, and extensive differences in sharing the
co-expressed targets can be observed. For example,
PCSK1 and PCSK2 form a unique convertase pair
because they share a vast majority (75% and 80%) of
their putative target molecules. Strikingly, PCSK5, the
enzyme that prefers negative rather than positive expres-
sion correlation with its putative targets shares few
genes with other PCSK enzymes. This finding under-
scores the dissimilar behavior of this enzyme in these
expression correlation analyses.
Intriguingly, the previously published sequence-based
PCSK comparisons resulted in nearly identical order of
similarity as did our shared putative target analysis pre-
sented in Table 2[6]. The only exception was PCSK7,
which is the structurally least similar enzyme with
FURIN. In our analyses it has the second highest number
of identical putative targets with FURIN. The substrate
sharing between these two enzymes is supported by
previous experimental data and a likely explanation for
the observed biological redundancy of PCSK7 [24-26].
To further dissect the specificity-redundancy issue we
classified the identified target molecules according to a
calculated ‘uniqueness value’ (Additional File 5). First,
the protease targets were sorted in descending order
based on the correlation values with a specific PCSK
gene and ordinals were recorded. Then, the same was
done ascending, one by one, for all the other PCSK
genes. Finally, the ordinal numbers for each of the cor-
relating putative targets were summed up. Consequently,
lower value of the summed ordinals predicts more
unique PCSK - target pair. In other words, this ‘unique-
ness value’ assorts the likelihood by which a PCSK
enzyme is coordinately and specifically expressed with a
target molecule and can therefore offer insights into the
biological function and degree of substrate redundancy
of these enzymes.
In addition to the direct modulation by transcription
activators and repressors expression of a gene can also be
dictated at epigenetic level. Clustering of the PCSK target
genes in chromosomes might thus imply a coordinated,
genome-structure manner of regulation. To test whether
such clusters exist we performed a clustering analysis of
the putative PCSK target genes. Intriguingly, marked dif-
ferences could be observed; the putative targets for the
PCSK1 and PCSK7 form several chromosomal clusters
(six clusters for PCSK1, five clusters for PCSK7), whereas
for example there was no chromosomal clustering of the
PCSK6 target genes (Additional File 6). This could sug-
gest that some of the PCSK enzymes regulate the expres-
sion of their targets by participating in the epigenetic
modulation while others prefer a direct transcription fac-
tor based induction. Obviously, experimental evidence is
required to test this hypothesis.
Exploring the putative substrates beyond the PCSK
consensus sequence
The minimal PCSK target sequence contains basic
amino acids arginine and lysine, which are critical for
Table 2 Fraction of putative PCSK targets found within another PCSK’s putative targets
PCSK1 PCSK2 FURIN, f FURIN, gpc PCSK4 PCSK5 PCSK6 PCSK7 n
PCSK1 1 0.800 0 0 0.006 0 0.163 0 160
PCSK2 0.753 1 0 0 0 0 0.276 0 170
FURIN, f 0 0 1 0.846 0.115 0 0.026 0.077 78
FURIN, gpc 0 0 0.410 1 0.130 0.006 0.019 0.087 161
PCSK4 0.010 0 0.087 0.202 1 0 0.106 0.010 104
PCSK5 0 0 0 0.009 0 1 0 0.095 116
PCSK6 0.158 0.285 0.012 0.018 0.067 0 1 0 165
PCSK7 0 0 0.054 0.126 0.009 0.099 0 1 111
f = furin-specific cleavage site
gpc = general PCSK cleavage site
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the substrate to bind into the negatively charged enzy-
matically active cleft in the PCSK enzymes. The flanking
regions around the minimal consensus sequence in the
PCSK targets are less well examined. The amino acid
compositions around the recognition sequences were
first visualized using MultiDisp server (http://bioinf.uta.
fi/cgi-bin/MultiDisp.cgi, Figure 4, Additional File 7). We
focused on twenty amino acid residues close to the
putative PCSK cleavage site (upstream P1-P10, down-
stream P1’-P10’) to see if any common patterns can be
identified for a specific PCSK enzyme. As expected, the
predicted target sequences for all PCSKs clearly favored
either arginine or lysine at the P1 and P2, and P4.
When the targets of a PCSK were explored individually
many amino acid residues with only subtle preferences
could be seen at other positions. To perform a systema-
tic analysis of the preferred/unfavored residues we then
calculated the frequency difference from a mean for
each amino acid at sites P10-P10’ using the amino acid
frequency tables from MultiDisp (Figure 4).
Our analysis showed minor differences in the target
alignment segment, where a consensus sequence of Rx
[KR]R is favored. Putative targets of PCSK7 have a slight
enrichment of arginine in the P2. This might be
explained by the PCSK7 b8-b9 loop having a glycine
aligning the P2 site instead of the glutamate in PCSK1/
4/5/6 or the phenylalanine in PCSK2. Small glycine resi-
due might allow more space for the bulky arginine side
chain. In addition, PCSK5, which showed putative target
enrichment in the bottom 5% correlating genes, seem to
have a stronger preference for lysine at this site when
compared to other PCSKs. Interestingly, when the inver-
sely expressed putative targets from the negatively corre-
lating genes for PCSK5 were analyzed we found a strong
preference for arginine at P2 site (Additional File 8).
PCSK4 appears to allow negative charged residues at the
P4 site, which cannot be explained in the electrostatics
of the PCSK4 residues interacting with the P4. Just out-
side the substrate alignment segment, at the P5, acidic
residues are preferred in all groups of putative targets,
except for PCSK7. It is also noteworthy that the putative
targets of PCSK7 have leucines enriched at sites P4, P5
and P7. The hydrophobic nature of leucine would sug-
gest higher extent of hydrophobic interactions between
PCSK7 and target sequences in contrast to other PCSKs.
We did not find strong patterns of favored amino
acids for the sites P1’-P10’ that would explain substrate
specificity of the PCSKs. However, position P5’ was
found to be quite variable and to slightly favor acidic
residues, with the exception of PCSK4. Glutamine and
alanine were found slightly enriched in the P7’ position
in PCSK5. These enriched residue types at certain posi-
tions could hint at sequence-specific substrate recogni-
tion, but additional studies are needed to prove their
contribution to the biological function.
Biochemical identification of PAPPA1 and ADAMTS6 as
novel FURIN substrates
As previously pointed out the coordinated expression of
PCSK and its substrates is supported by scattered
experimental evidence. In addition, a previous report
has convincingly shown the validity of ProP prediction
in selecting PCSK targets in FURIN deficient mouse
liver in vivo [27]. These data show that ProP can predict
the physiological PCSK processed proteins fairly accu-
rately, but also that the mainly co-expression experi-
ment data based FURIN prediction algorithm cannot
discriminate the physiological FURIN specific target
molecules from general PCSK targets. Our genome-wide
analysis identified several previously published targets
Figure 4 Amino acid occurrence of putative target molecules for different PCSK enzymes. Twenty residues (P10 - P10’) around the PCSK
cleavage sites of putative target molecules have been plotted for each PCSK enzymes (PCSK1-PCSK7, columns 1 - 7, respectively, in each
position). Rows correspond to different amino acids. Blue color indicates increased occurrence of a particular amino acid residue type in certain
position of the putative substrate when all PCSKs are considered, whereas red colors mean low occurrence of a specific amino acid. White
indicates an average occurrence frequency of a specific amino acid. The increase or decrease in occurrence is shown as a scale of percentages
and a combined data containing all PCSKs has been used as a comparison point. The scaling (-6 percentage to +6 percentage) is shown as a
color gradient below the figure. The potentially scissile bond P1-P1’ is marked with scissors.
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for the PCSK enzymes, for example, the list of putative
FURIN target molecules includes matrix metalloprotei-
nases (MMP11), growth factors (PDGFB), and cytokines
(BMP1) that have been previously been identified as
PCSK targets [25,28,29]. Notably, the list lacks a physio-
logical FURIN target TGFb1, which shows a highly
coordinated expression with FURIN in the tissues like
blood myeloid and lymphoid cells (correlation values in
GeneSapiens analysis of r = 0.743 and 0.596, respec-
tively) [30,31]. When exploring the putative target list of
PCSK1 and PCSK2 enzymes, which have a more
restricted expression pattern than FURIN, we noted that
several biological targets, such as proSAAS (ENSG
00000102109) and prosomatostatin (ENSG00000
157005), can be identified. Therefore, our approach
seems to work particularly efficiently when both PCSK
and its substrate have generally restricted expression. In
contrast, genome-wide approach may fall short in iden-
tifying tissue specific substrates for widely expressed
PCSK enzymes.
We validated our approach biochemically by identify-
ing novel PCSK target genes on our lists. We chose to
look for novel FURIN processed molecules from both
general PCSK and “FURIN specific” target lists. We
selected two highly correlating genes with a human-
mouse conserved PCSK target sequence ADAMTS6
(ENSG00000049192, correlation value 0.34) and
PAPPA1 (ENSG00000182752, correlation value 0.41),
which have not previously been experimentally shown
to be processed by FURIN. Further, we have previously
shown that in FURIN knock-out T cells ADAMTS6 is
down-regulated, which is in keeping with our theory
that the PCSK target molecules are coordinately regu-
lated with their converting enzyme [31]. In Figure 5A,
we blotted for endogenous ADAMTS6 molecule in
wild-type and FURIN knock-out CD4+ T cells with an
antibody that specifically recognizes the catalytic domain
of ADAMTS6. Our results show that the 97 kDA band
that represents the processed ADAMTS6 molecule is
clearly reduced in FURIN knock-out samples (Figure
kDa
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Figure 5 Proteolytic processing of ADAMTS6 and PAPPA1. A) Aliquots of CD4+ T cell lysates from wild-type and FURIN knock-out mice were
run on SDS-PAGE and ADAMTS6 and ACTIN were detected by Western blot. B and C) 293e cells were transfected with FURIN-myc-his or PCSK7-
flag together with wild-type, PCSK cleavage site mutated flag-PAPPA1-myc (mut) or PCSK7-favored leucines harboring flag-PAPPA1-myc (R3L)
constructs, and detected anti-flag or anti-Myc antibodies as indicated. Unprocessed PAPPA1 is indicated with an asterisk and processed with an
arrow. All experiments were repeated at least twice with similar results.
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5A). Furthermore, in Figure 5B we show that PAPPA1,
which contains putative PCSK target sites in its N-ter-
minus is only processed if FURIN cDNA is co-expressed
with the N-terminal part of PAPPA1. The mutation of
the putative FURIN target sequences in PAPPA1 makes
it resistant for FURIN’s proteolytic activity. These results
unequivocally show that expression correlation analysis
combined with PCSK target site prediction can be used
to identify novel target molecules for the PCSK
enzymes.
Finally, to test whether the enrichment of certain
amino acids around the cleavage site would change the
target preferences for PCSKs we mutated arginines at
P4, P5 and P7 positions of PAPPA1 into PCSK7-favored
leucines (Arg24/26/27Leu, Figure 5C). In these overex-
pression experiments wild-type N-terminus of PAPPA1
was processed by PCKS7 to comparable extent with
FURIN, a finding that underscores again the limitations
of this approach in identifying specific substrates. How-
ever, PAPPA1 construct that harbors the favored leu-
cines (R3L) was much more potently processed by
PCSK7 when compared with wild-type PAPPA1. This
result confirms that the abovementioned exploration of
the cleavage site flanking sequences may indeed give
insights to the substrate preferences of a PCSK. How-
ever, true in vivo identification of such critical amino
acids would require an analysis using for example
knock-in mice or mutant patient cell lines.
Conclusions
The biological significance of the PCSK enzymes is
indisputable and interfering with their activity holds
promise for future therapies in diseases ranging from
atherosclerosis to cancers and infections. Therefore,
understanding the determinants of the substrate speci-
ficity of PCSKs enzymes is of utmost importance. Tra-
ditional biochemical experiments where a PCSK is co-
expressed in vitro with its putative target molecule
have certainly improved our understanding on the
PCSK function, but can also lead to misinterpretation
on the biological role of a PCSK. Our data presented
herein shows that most PCSK enzymes are coordi-
nately expressed with their putative target proteins.
Exploring this phenomenon can complement the in
vitro experiments and can also offer insights into the
true biological function of these enzymes in health and
disease.
Methods
Expression data and correlation
Expression data and correlation values used in the ana-
lyses were obtained from the GeneSapiens database,
described elsewhere (http://www.genesapiens.org, [16]).
Briefly, expression correlations of all the PCSK genes
with all the other genes in the human genome (n =
17330) were analyzed in large number (n = 1869) of
samples. Only healthy samples over the whole spectrum
of human tissues (altogether 43 distinct tissue types)
were used. Expression correlation values for all the
PCSK genes are provided in the Additional File 2.
Data analysis for correlation was done with R. The
correlation metric used was Pearson correlation coeffi-
cient. The coefficient was calculated using all samples
that had expression values for both genes in the analysis,
with a minimum requirement of 10 common samples.
Additional File 2 provides two correlation coefficients,
non-log and log. Log values are correlations for gene
expression patterns that have undergone log2 transfor-
mation, and non-log values are determined straight
from the measured expression values. The non-log
values were used in this analysis.
Genes with strong positive correlation in expression
with PCSK (top 5%) and strong negative correlation in
expression with PCSK (bottom 5%) were extracted from
the expression correlation lists for all the PCSK genes
(Figure 2, Additional File 2). This resulted 867 (= 17330
× 0.05; 861 for PCSK4 (= 17215 × 0.05)) genes correlat-
ing strongly (positively or negatively) with PCSK gene
expression. Secondly, as proprotein convertases and
their substrates were assumed to be present in the same
cell compartments, the presence of a protein secretion
signal peptide in correlates (minimum 11 amino acid
long) was required. Thirdly, proprotein cleavage sites
outside of the signal peptide were predicted with the
ProP server (http://www.cbs.dtu.dk/services/ProP/) using
the general PC prediction [17]. Narrowing down the top
5% and bottom 5% gene lists with these inclusion cri-
teria of signal peptide and proprotein cleavage site
yielded some 67 to 170 highly (positively or negatively)
correlating genes per PSCK gene (Table 1, Additional
File 2). Highly positively expression correlated genes
that fulfilled the inclusion criteria were named as ‘puta-
tive PCSK targets’.
PCSK protein modeling
To investigate the interactions of the putative targets
with the catalytic cleft, we modelled the different PCSKs
with the program Modeller 9v7 using the crystallo-
graphic structure of FURIN as template (PDB ID: 1P8J
[11]). The models were in good agreement with those
previously described [6], kindly provided by Stefan Hen-
rich. The conservation of the substrate-recognition site
was evaluated by comparing the sequences of PCs from
26 species, covering altogether 152 amino acid
sequences. The sequence alignments were generated
using ClustalW2 [32]. The conserved (>95%) residues
were visualized into the crystal structure of FURIN
using program PyMOL 1.4.
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Substrate recognition sequence
The top-correlates containing signal peptide sequences
were subjected to computational screening of PCSK
cleavage sites. The cleavage sites found in the putative
target proteins were analyzed using the MultiDisp tool
that plots the amino acid frequencies (Figure 4, Addi-
tional File 7, Additional File 8). The frequencies were
also compared to the mean of all putative cleavage sites
(Figure 4).
Chromosomal clustering of targets identified
A clustering analyses for the putative targets identified
was performed using CROC software (http://metage-
nomics.uv.es/CROC, [33]). A sliding window of 20
genes, minimum number of three genes expected per
cluster and Benjamini&Hochberg correction for multiple
testing were applied for statistical analysis.
In vitro identification of the FURIN target molecules
DNA sequences encoding the N-terminal amino acids
Arg2 to Ala200 of human PAPPA1 with N-terminal
FLAG and hemagglutin (HA) tags from GeneArt (http://
www.geneart.com) and full-length human FURIN from
ATCC were both cloned into pcDNA3.1-myc-his
expression vector. PCSK7-flag plasmid was a kind gift
from Prof. John Creemers (Center for Human Genetics,
K. U. Leuven, Leuven, Belgium). PAPPA1R3L construct
(Arg24/26/27Leu) was cloned using QuikChange Muta-
genesis Kit (Stratagene). HEK 293e cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented by 10% fetal calf serum (FCS) and 1% peni-
cillin/streptomycin. Cells were transiently transfected
with FURIN or PCSK7 and PAPPA1 constructs using
TurboFect transfection reagent (Fermentas) according to
the manufacturer’s instructions. 48 hours post-transfec-
tion, cells were washed once with cold phosphate-buf-
fered saline (PBS), and lysed into Triton-X lysis buffer.
CD4+ cells from spleen and lymph nodes of wild-type
and T-cell specific furin knock-out mice [31] were puri-
fied by positive selection using magnetic beads (Miltenyi
Biotech) and lysed into Triton-X lysis buffer. Aliquots of
cell lysates were run on 12% SDS-PAGE gels. Western
blotting was performed using ADAMTS6 (ab50647,
Abcam), actin (Millipore), myc and FLAG (Sigma)
antibodies.
Additional material
Additional file 1: PCSK sequences used for Figure 1. Altogether 152
PCSK sequences were used.
Additional file 2: Whole genome expression correlations for PCSK1-
7 genes. Non-logarithmic and logarithmic correlations as well as p
values and common data points are listed. Genes in blue are bottom 5%
genes that fulfill the inclusion criteria of signal peptide and PCSK
recognition site. Red ones are the corresponding genes for top 5%.
Additional file 3: Mutual expression correlation between the PCSK
gene pairs over the whole spectrum of healthy tissues.
Additional file 4: Mutual expression correlation between the PCSK
gene pairs specified in different anatomical structures.
Additional file 5: Uniqueness expression correlation values of
putative PCSK targets. The uniqueness values for putative targets were
counted as follows: First, the correlating genes were sorted descending
by correlation values with specific PCSK gene and ordinals were
recorded. Then, the same was done ascending, one by one, for all the
other PCSK genes. Finally, the ordinal numbers for each of the
correlating putative targets were summed up. The lower the summed
value the more unique the expression correlation is for the specific PCSK
gene.
Additional file 6: Chromosomal clustering of putative PCSK targets.
Additional file 7: MultiDisp figures of potential PCSK target
sequences. The sequences were predicted from the group of top-
correlated gene translations using the general PC prediction and signal
peptide prediction methods on the ProP 1.0 server (http://www.cbs.dtu.
dk/services/ProP/). Potential target peptides from signal peptide-
containing sequences were restricted to ten residues upstream (P10-P1)
and downstream (P1’-P10’) of the predicted cleavage site. Amino acid
compositions at each site in the groups of potential targets for each
PCSK were plotted using MultiDisp (http://bioinf.uta.fi/cgi-bin/MultiDisp.
cgi) that scales the character heights based on amino acid frequency.
Scissors and dotted line mark the predicted cleavage site.
Additional file 8: Amino acid occurrence of putative target
molecules for PCSK5. Twenty residues (P10 - P10’, marked with
numbers 10 - 10’) around the PCSK cleavage sites of highly correlating
genes have been plotted for PCSK5. Top (t) and bottom (b) groups are
shown for each amino acid type. Blue color indicates increased
occurrence of a particular amino acid residue type in certain position of
the putative substrate when all PCSKs are considered, whereas red colors
mean low occurrence of a specific amino acid. White indicates an
average occurrence frequency of a specific amino acid. The increase or
decrease in occurrence is shown as a scale of percentages and a
combined data containing all PCSKs has been used as a comparison
point. The scaling (-6 percentage to +6 percentage) is shown as a color
gradient below the figure. The potentially scissile bond P1-P1’ is marked
with scissors and dashed line.
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